|Amgen Inc -- USA Stock|| |
USD 183.55 0.05 0.0272%
Senior Vice President - Business Development
Mr. David A. Piacquad is the Senior Vice President Business Development of Amgen Inc. Mr. Piacquad joined the Company in June 2010 and, until January 2014, served as Vice President, Strategy and Corporationrationrate Development. From January 2014 to March 2014, Mr. Piacquad served as Vice President, Business Development. Prior to joining the Company, from December 2009 to June 2010, Mr. Piacquad was Principal of David A. Piacquad Consulting LLC. From March 2006 to December 2009, Mr. Piacquad served as Senior Vice President, Business Development and Licensing for ScheringPlough Corporationrationration. Prior to ScheringPlough, Mr. Piacquad served in a series of leadership roles in finance and business development at JJ, with his last position being Vice President, Ventures and Business Development.
Age: 59 President Since 2014
David Piacquad Latest Insider Activity
The company has return on total asset (ROA)
of 8.32 %
which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 7.18 %
meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.